

SAFETY IN THE USE OF JAK INHIBITORS IN CHRONIC INFLAMMATORY DISEASES



Cuerpo Ibáñez L., Sánchez Serrano JL., Drozd Vergara A., De Mora Alfaro MJ., Torres Tendero IC., Clemente Pradillo N.

BACKGROUND AND IMPORTANCE



Safety Alert (MUH (FV), 08/2022)
in November 2022

- ➔ **Risk of major adverse cardiovascular events (MACE) and malignancies** in patients treated with iJAK
- ➔ A series of **recommendations** were established regarding their use in **patients over 65 years of age and with CVRF or for the development of neoplasia.**

OBJETIVES



To evaluate the appropriate use of iJAK in a 666-bed hospital according to AEMPS recommendations.

MATERIAL AND METODS

- ★ **Retrospective observational study** of patients treated with iJAK baricitinib, tofacitinib, upadacitinib and filgotinib from July 2021-March 2024.
- ★ We analyzed which **patients continued with iJAK** after the AEMPS recommendation despite having **risk factors** and whether or not they had a **therapeutic alternative**.
- ★ **Sources consulted:** : the Outpatient Management module of Farmatools® and the clinical history of the patients. **Data analysis:** Excell®
- ★ **Variables collected:** age, sex, risk factors of MACE and malignant neoplasms and existence of a treatment alternative; before and after the Health Alert.

RESULTS



151 patients
Mean age: 52 years

♀ 69% women

Before the alert 96 patients treated with iJAK

71% had some risk factors → 27% stopped treatment and 73% continued treatment

Of those who continued 41% had a therapeutic alternative and 59% did not

After the alert 64 patients started treatment with iJAK.

48% had some risk factors

42% with treatment alternatives and 58% without alternatives

Comparison of patients before and after the alert:

- Before: 71% with risk factors, of which 30% had an alternative treatment
- After: 63% with risk factors, of which 40% had an alternative treatment



CONCLUSIONS

- No significant changes were observed after the alert described, with the benefit of the treatment being valued more than the risk.
- The presence of a multidisciplinary team in which the pharmacist is integrated can be essential when proposing therapeutic alternatives that guarantee patient safety.

